Defining antimicrobial resistance in cystic fibrosis

Timothy J Kidd; Rafael Canton; Miquel Ekkelenkamp; Helle Krogh Johansen; Peter Gilligan; John J LiPuma; Scott C Bell; J Stuart Elborn; Patrick A Flume; Donald R VanDevanter; Valerie J Waters; Antimicrobial Resistance in Cystic Fibrosis International Working Group

doi:10.1016/j.jcf.2018.08.014

Defining antimicrobial resistance in cystic fibrosis

Timothy J Kidd, Rafael Canton, Miquel Ekkelenkamp, Helle Krogh Johansen, Peter Gilligan, John J LiPuma, Scott C Bell, J Stuart Elborn, Patrick A Flume, Donald R VanDevanter, Valerie J Waters, Antimicrobial Resistance in Cystic Fibrosis International Working Group

Department of Clinical Medicine

27 Citations (Scopus)

Abstract

Antimicrobial resistance (AMR) can present significant challenges in the treatment of cystic fibrosis (CF) lung infections. In CF and other chronic diseases, AMR has a different profile and clinical consequences compared to acute infections and this requires different diagnostic and treatment approaches. This review defines AMR, explains how it occurs, describes the methods used to measure AMR as well as their limitations, and concludes with future directions for research and development in the area of AMR in CF.

Original language	English
Journal	Journal of Cystic Fibrosis
Volume	17
Issue number	6
Pages (from-to)	696-704
Number of pages	9
ISSN	1569-1993
DOIs	https://doi.org/10.1016/j.jcf.2018.08.014
Publication status	Published - Nov 2018

Access to Document

10.1016/j.jcf.2018.08.014

http://www.cysticfibrosisjournal.com/article/S1569199318307975/pdf

Cite this

Kidd, T. J., Canton, R., Ekkelenkamp, M., Johansen, H. K., Gilligan, P., LiPuma, J. J., Bell, S. C., Elborn, J. S., Flume, P. A., VanDevanter, D. R., Waters, V. J., & Antimicrobial Resistance in Cystic Fibrosis International Working Group (2018). Defining antimicrobial resistance in cystic fibrosis. Journal of Cystic Fibrosis, 17(6), 696-704. https://doi.org/10.1016/j.jcf.2018.08.014

Kidd, TJ, Canton, R, Ekkelenkamp, M, Johansen, HK, Gilligan, P, LiPuma, JJ, Bell, SC, Elborn, JS, Flume, PA, VanDevanter, DR, Waters, VJ & Antimicrobial Resistance in Cystic Fibrosis International Working Group 2018, 'Defining antimicrobial resistance in cystic fibrosis', Journal of Cystic Fibrosis, vol. 17, no. 6, pp. 696-704. https://doi.org/10.1016/j.jcf.2018.08.014

@article{30077aabf9504b34b0459fce8fb59ce2,

title = "Defining antimicrobial resistance in cystic fibrosis",

abstract = "Antimicrobial resistance (AMR) can present significant challenges in the treatment of cystic fibrosis (CF) lung infections. In CF and other chronic diseases, AMR has a different profile and clinical consequences compared to acute infections and this requires different diagnostic and treatment approaches. This review defines AMR, explains how it occurs, describes the methods used to measure AMR as well as their limitations, and concludes with future directions for research and development in the area of AMR in CF.",

author = "Kidd, {Timothy J} and Rafael Canton and Miquel Ekkelenkamp and Johansen, {Helle Krogh} and Peter Gilligan and LiPuma, {John J} and Bell, {Scott C} and Elborn, {J Stuart} and Flume, {Patrick A} and VanDevanter, {Donald R} and Waters, {Valerie J} and {Antimicrobial Resistance in Cystic Fibrosis International Working Group}",

year = "2018",

month = nov,

doi = "10.1016/j.jcf.2018.08.014",

language = "English",

volume = "17",

pages = "696--704",

journal = "Journal of Cystic Fibrosis",

issn = "1569-1993",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Defining antimicrobial resistance in cystic fibrosis

AU - Kidd, Timothy J

AU - Canton, Rafael

AU - Ekkelenkamp, Miquel

AU - Johansen, Helle Krogh

AU - Gilligan, Peter

AU - LiPuma, John J

AU - Bell, Scott C

AU - Elborn, J Stuart

AU - Flume, Patrick A

AU - VanDevanter, Donald R

AU - Waters, Valerie J

AU - Antimicrobial Resistance in Cystic Fibrosis International Working Group

PY - 2018/11

Y1 - 2018/11

N2 - Antimicrobial resistance (AMR) can present significant challenges in the treatment of cystic fibrosis (CF) lung infections. In CF and other chronic diseases, AMR has a different profile and clinical consequences compared to acute infections and this requires different diagnostic and treatment approaches. This review defines AMR, explains how it occurs, describes the methods used to measure AMR as well as their limitations, and concludes with future directions for research and development in the area of AMR in CF.

AB - Antimicrobial resistance (AMR) can present significant challenges in the treatment of cystic fibrosis (CF) lung infections. In CF and other chronic diseases, AMR has a different profile and clinical consequences compared to acute infections and this requires different diagnostic and treatment approaches. This review defines AMR, explains how it occurs, describes the methods used to measure AMR as well as their limitations, and concludes with future directions for research and development in the area of AMR in CF.

U2 - 10.1016/j.jcf.2018.08.014

DO - 10.1016/j.jcf.2018.08.014

M3 - Review

C2 - 30266518

SN - 1569-1993

VL - 17

SP - 696

EP - 704

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

IS - 6

ER -

Defining antimicrobial resistance in cystic fibrosis

Abstract

Access to Document

Fingerprint

Cite this